Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018.
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions.
Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
After years of professional training to become a qualified specialist its vital that Ophthalmologists get the right advice to protect their future income potential. Let Legacy help evaluate the best options for you.
Legacy would like to offer a free, no obligation, review of your insurance needs - business and professional.
Please see our website for details of our services: http://www.legacygroup.co.nz/ and contact Simon Rupapera for a confidential discussion - DDI 09 354 5500,
M 021 895 114 E firstname.lastname@example.org